...
首页> 外文期刊>European review for medical and pharmacological sciences. >Expression of lncRNA-ATB in laryngeal carcinoma and its relationship with prognosis
【24h】

Expression of lncRNA-ATB in laryngeal carcinoma and its relationship with prognosis

机译:LNCRNA-ATB在喉癌中的表达及其与预后的关系

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: The aim of this study was to investigate the expression of long non-coding RNA (lncRNA)-ATB in laryngeal carcinoma (LNCa) and its relationship with the prognosis. PATIENTS AND METHODS: The expression of lncRNA-ATB was examined in laryngeal carcinoma tissue specimens, as well as in normal ones by quantitative real-time polymerase chain reaction (qRT-PCR), and the interplay between lncRNA-ATB levels and clinical indicators was analyzed. In addition, the diagnostic value of lncRNA-ATB for LNCa was assessed by receiver operating characteristic (ROC) curve analysis. The patients were followed up for 5 years and the survival analysis was conducted by Kaplan-Meier test. Finally, the Cox regression model was used to analyze the factors affecting the prognosis of patients. RESULTS: LncRNA-ATB expression was markedly enhanced in laryngeal carcinoma tissue samples compared to the corresponding normal ones, which was relevant to T grade and clinical stage. For the diagnosis of laryngeal carcinoma using lncRNA-ATB, the area under the ROC curve (AUC) was 0.8672, the diagnostic threshold was 3.895, and the sensitivity and specificity were 83.02% and 76.42%, respectively. In addition, the overall survival rate of patients with high expression of lncRNA-ATB was markedly lower than those in low expression group. Meanwhile, T grade, clinical stage and lncRNA-ATB are found as three independent factors influencing the prognosis of LNCa. CONCLUSIONS: LncRNA-ATB was highly expressed in laryngeal carcinoma tissues, which was not conducive to the prognosis of patients. Therefore, this molecular marker has potential to become a new biomarker for the diagnosis and prognosis prediction of patients with LNCa.
机译:目的:本研究的目的是探讨长期非编码RNA(LNCRNA)-ATB在喉癌(LNCA)中的表达及其与预后的关系。患者和方法:通过定量实时聚合酶链反应(QRT-PCR),在喉癌组织标本中检查LNCRNA-ATB的表达,以及正常的实时聚合酶链反应(QRT-PCR),LNCRNA-ATB水平与临床指标之间的相互作用是分析。此外,通过接收器操作特征(ROC)曲线分析评估LNCA的LNCRNA-ATB的诊断值。患者随访5年,并通过Kaplan-Meier试验进行存活分析。最后,COX回归模型用于分析影响患者预后的因素。结果:与相应的正常情况相比,LNCRNA-ATB表达在喉癌组织样本中显着增强,与T级和临床阶段相关。对于使用LNCRNA-ATB的喉癌癌的诊断,ROC曲线(AUC)下的面积为0.8672,诊断阈值为3.895,敏感性和特异性分别为83.02%和76.42%。此外,LNCRNA-ATB高表达患者的总存活率明显低于低表达组。同时,发现T级,临床阶段和LNCRNA-ATB是影响LNCA预后的三个独立因素。结论:LNCRNA-ATB在喉癌组织中高度表达,不利于患者的预后。因此,该分子标记物有可能成为LNCA患者诊断和预后预测的新生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号